Polar Asset Management Partners’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Polar Asset Management Partners’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-148,800	Closed	-$2.65K	–	1296
2022 Q4	$2.65K	Hold	148,800	–	–	﹤0.01%	1176
2022 Q3	$12K	Hold	148,800	–	–	﹤0.01%	1240
2022 Q2	$12K	Hold	148,800	–	–	﹤0.01%	1260
2022 Q1	$30K	Hold	148,800	–	–	﹤0.01%	1082
2021 Q4	$80K	Sell	148,800 -26,300	-15%	-$14.9K	﹤0.01%	1157
2021 Q3	$105K	Hold	175,100	–	–	﹤0.01%	1087
2021 Q2	$133K	Buy	+175,100	New	+$106K	﹤0.01%	996

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Polar Asset Management Partners's IBER.WS Position: Q1 2023 in Review

Polar Asset Management Partners sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 148,800 shares — an estimated $2.65K sold.

Polar Asset Management Partners first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $133K in Q2 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Polar Asset Management Partners reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Polar Asset Management Partners sold 148,800 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $2.65K.
Polar Asset Management Partners first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
Polar Asset Management Partners's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $133K in Q2 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Polar Asset Management Partners's 13F filing for Q1 2023, filed 15 May 2023.